Dhanvantri Jeevan Rekha Limited (**DJRL**) is a prominent multi-specialty healthcare provider headquartered in **Meerut, Uttar Pradesh**. Established in **1993**, the company has spent over **31 years** evolving into a critical tertiary care hub for Western Uttar Pradesh. Listed on the **Bombay Stock Exchange (BSE)**, DJRL operates a high-tech diagnostic and therapeutic center designed to provide "cashless and paperless" medical services to a diverse socio-economic demographic. --- ### **Core Medical Specializations and Clinical Infrastructure** DJRL operates a "State-of-the-Art" facility located at **1 Saket, Meerut**, functioning as a comprehensive setup where diagnostic and therapeutic services are integrated under one roof. The clinical model emphasizes high-end super-specialty care alongside essential emergency services. * **Advanced Cardiac Care:** The facility features a fully operational **Cath Lab** capable of performing complex interventional procedures, including **Angiography, Angioplasty, Pacemaker Implantation, and Valvuloplasty**. * **Super-Specialty Departments:** The hospital provides dedicated care in **Neurology, Orthopedics, Gastroenterology, Urology, Nephrology (including a specialized Dialysis unit), and General Surgery**. * **Emergency & Diagnostic Services:** The center operates **24-hour emergency care** and maintains a full-scale diagnostic wing to support both Outpatient (**OPD**) and Inpatient (**IPD**) departments. * **Government Integration:** The company is a key participant in the **Ayushman Bharat - PMJAY** scheme, ensuring that advanced healthcare is accessible to government-empanelled beneficiaries. | Infrastructure Feature | Specification / Detail | | :--- | :--- | | **Location** | **1, Saket, Meerut, Uttar Pradesh** | | **Operational Longevity** | Established **1993** (**31+ Years**) | | **Key Technology** | **Cath Lab**, EHR Systems, Advanced Diagnostic Imaging | | **Asset Oversight** | Physical verification of PPE conducted every **3 years** | | **Workforce Size** | **98 permanent employees** (as of March 31, 2025) | --- ### **Strategic Growth Drivers and Market Positioning** DJRL’s strategy is aligned with the structural transformation of the Indian healthcare sector, characterized by a shift toward private-sector dominance and digital integration. * **Macroeconomic Tailwinds:** The company is positioned to benefit from the Indian government’s target to increase public health spending to **2.5% of GDP by 2025**. * **Digital Health Transition:** DJRL is actively transitioning toward **Digital Health Solutions**, incorporating **Electronic Health Records (EHRs)**, mobile health applications, and **remote patient monitoring** to enhance operational efficiency and patient reach. * **Localization of Supply Chain:** The company anticipates reduced capital expenditure (CAPEX) as the Indian medical device market is projected to grow from **$11 billion** to **$49.5 billion by 2025**, fostering more affordable domestic procurement. * **Demographic Shifts:** Management is monitoring the **Home Healthcare** sector, which is projected to reach **$21.3 billion by 2027** (growing at a **19.2% CAGR**), driven by an aging population and the rising prevalence of chronic diseases. --- ### **Financial Performance and Capital Structure** The company has demonstrated a successful financial turnaround, moving from a net loss in **FY23** to consistent profitability in **FY25**. DJRL maintains a highly conservative balance sheet with a focus on self-funded growth. #### **Comparative Financial Summary** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Operating Income** | **₹22.65 Crore** | **₹20.47 Crore** | **₹17.68 Crore** | | **Net Profit / (Loss)** | **₹50.61 Lakhs** | **₹16.52 Lakhs** | **(₹21.66 Lakhs)** | | **Revenue Growth (YoY)** | **10.70%** | **15.78%** | **5.43%** | | **Paid-up Equity Capital** | **₹4.1 Crore** | **₹4.1 Crore** | **₹4.1 Crore** | #### **Capital Allocation and Liquidity** * **Debt-Free Status:** The company remains **Debt-Free** and does not utilize sanctioned working capital limits exceeding **₹5 Crore**. * **Reinvestment Strategy:** The Board recommended **No Dividend** for **FY25**, opting to redirect all surplus funds into **Capital Expenses**, specifically for **building renovations**, equipment maintenance, and the launch of new departments like **Gastroenterology**. * **Credit Risk:** Trade receivables are primarily derived from medical services; the company operates without requiring collateral, citing no significant history of credit defaults. * **Corporate Structure:** DJRL has **no subsidiaries, associates, or joint ventures**, maintaining a simplified corporate structure. --- ### **Risk Management and Regulatory Landscape** DJRL operates in a high-overhead environment where regulatory changes and human capital costs significantly impact margins. * **Cost Pressures:** The company faces rising input costs due to **minimum wage revisions** and **real estate inflation**. Furthermore, the high cost of imported medical equipment is sensitive to **INR/USD exchange rate** volatility. * **Regulatory Risks:** Potential **price capping** on medical procedures by regulatory bodies poses a risk to service standards. However, the company mitigates this by focusing on volume and operational efficiency. * **Epidemiological Burden:** With **Non-Communicable Diseases (NCDs)** accounting for **60% of deaths in India** (approx. **0.59 crore** annually), the company must continuously reinvest in specialized care for chronic conditions. * **Governance and Compliance:** * **Internal Audit:** New internal auditors were appointed in **May 2025** to strengthen oversight. * **Risk Policy:** A formalized **Risk Management Policy** is in place to evaluate strategic and financial threats. * **Solvency:** No material uncertainty exists regarding the company's ability to meet liabilities within the next **one year**. * **Audit Exemptions:** The company is not required to maintain cost records under **Section 148** or constitute a formal Risk Management Committee under **Regulation 21 of SEBI (LODR)** due to its current scale. --- ### **Future Outlook** DJRL is focused on consolidating its leadership in the **Western Uttar Pradesh** region by balancing **moderate service rates** with high-end clinical outcomes. By pursuing **NABH Accreditation** and expanding into emerging segments like **telemedicine** and **specialized nephrology**, the company aims to capture the growing healthcare demand from India's expanding middle class and the aging population.